Paper30953333
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
Akizawa T and 4 others. Adv Ther, 2019. Cited by 79 papers, by iCite.
Cite this record
ConductScience Library. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial. Papers, record 30953333. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30953333
- Disease
- anemia172 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
- PubMed
- Publication types
- Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anemia | Major topic |
| Chronic Disease | Major topic |
| Glycine | Major topic |
| Isoquinolines | Major topic |
| Renal Insufficiency, Chronic | Major topic |
| Adult | |
| Aged | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Japan | |
| Male | |
| Middle Aged | |
| Placebo Effect |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01964196 | ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis- | Derived from the trial | Yes |
Source ClinicalTrials.gov
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17557118 | Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). | J Clin Invest | 2007 | https://conductscience.org/library/papers/17557118 | PubMed |
| 2 | 26054543 | Erythropoietin Synthesis in Renal Myofibroblasts Is Restored by Activation of Hypoxia Signaling. | J Am Soc Nephrol | 2016 | https://conductscience.org/library/papers/26054543 | PubMed |
| 3 | 17108343 | Correction of anemia with epoetin alfa in chronic kidney disease. | N Engl J Med | 2006 | https://conductscience.org/library/papers/17108343 | PubMed |
| 4 | 19218474 | Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). | Clin J Am Soc Nephrol | 2009 | https://conductscience.org/library/papers/19218474 | PubMed |
| 5 | 26494833 | Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients. | J Am Soc Nephrol | 2016 | https://conductscience.org/library/papers/26494833 | PubMed |
| 6 | 30022586 | Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review. | Ther Apher Dial | 2018 | https://conductscience.org/library/papers/30022586 | PubMed |
| 7 | 27094610 | Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. | Clin J Am Soc Nephrol | 2016 | https://conductscience.org/library/papers/27094610 | PubMed |
| 8 | 28371815 | Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. | Nephrol Dial Transplant | 2017 | https://conductscience.org/library/papers/28371815 | PubMed |
| 9 | 26846333 | Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. | Am J Kidney Dis | 2016 | https://conductscience.org/library/papers/26846333 | PubMed |
| 10 | 9718377 | The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. | N Engl J Med | 1998 | https://conductscience.org/library/papers/9718377 | PubMed |
| 11 | 23291219 | Regulation of erythropoiesis by hypoxia-inducible factors. | Blood Rev | 2013 | https://conductscience.org/library/papers/23291219 | PubMed |
| 12 | 20609178 | 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. | Ther Apher Dial | 2010 | https://conductscience.org/library/papers/20609178 | PubMed |
| 13 | 19880844 | A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19880844 | PubMed |
| 14 | 16678659 | KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. | Am J Kidney Dis | 2006 | https://conductscience.org/library/papers/16678659 | PubMed |
| 15 | 26238121 | Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. | Nephrol Dial Transplant | 2015 | https://conductscience.org/library/papers/26238121 | PubMed |
| 16 | 19339088 | Revised equations for estimated GFR from serum creatinine in Japan. | Am J Kidney Dis | 2009 | https://conductscience.org/library/papers/19339088 | PubMed |
| 17 | 15142852 | Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. | Am J Physiol Regul Integr Comp Physiol | 2004 | https://conductscience.org/library/papers/15142852 | PubMed |
| 18 | 23379486 | Hepcidin is a potential regulator of iron status in chronic kidney disease. | Ther Apher Dial | 2013 | https://conductscience.org/library/papers/23379486 | PubMed |
| 19 | 20203166 | The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. | Clin J Am Soc Nephrol | 2010 | https://conductscience.org/library/papers/20203166 | PubMed |
| 20 | 28118622 | Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients. | Am J Nephrol | 2017 | https://conductscience.org/library/papers/28118622 | PubMed |
Cited by60
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 79 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42834713 | Acute Kidney Injury and Heart Failure Risk with Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors: A Network Meta-Analysis. | Clin Pharmacol Ther | 2026 | https://conductscience.org/library/papers/42834713 | PubMed |
| 42819330 | Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on transfusion and intravenous iron use in chronic kidney disease anemia: a systematic review and meta-analysis. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42819330 | PubMed |
| 42358369 | Thrombotic outcomes and mortality with roxadustat for anemia in chronic kidney disease: a systematic review and meta-analysis of randomized trials. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42358369 | PubMed |
| 41633330 | Efficacy and safety of prolyl hydroxylase inhibitors for anemia in chronic kidney disease: a network meta-analysis. | Ren Fail | 2026 | https://conductscience.org/library/papers/41633330 | PubMed |
| 41613326 | Frequency-reduction strategy of roxadustat in patients undergoing peritoneal dialysis: a multi-center retrospective cohort study. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/41613326 | PubMed |
| 41479171 | Safety Profile of Roxadustat in Anemic Patients: A Meta-Analysis of 21 RCTs. | Medeni Med J | 2025 | https://conductscience.org/library/papers/41479171 | PubMed |
| 41239296 | Network meta-analysis of HIF-prolyl hydroxylase inhibitors for anemia in dialysis-dependent and non-dialysis CKD: effects on hemoglobin, iron markers, and adverse clinical outcomes. | BMC Nephrol | 2025 | https://conductscience.org/library/papers/41239296 | PubMed |
| 41155680 | Safety of Roxadustat in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41155680 | PubMed |
| 40303227 | Randomized Trial of Lower-Dose Roxadustat Efficacy and Safety in Non-Dialysis-Dependent CKD-Associated Anemia. | Kidney Int Rep | 2025 | https://conductscience.org/library/papers/40303227 | PubMed |
| 40281613 | The Roxadustat (FG-4592) ameliorates tubulointerstitial fibrosis by promoting intact FGF23 cleavage. | Cell Commun Signal | 2025 | https://conductscience.org/library/papers/40281613 | PubMed |
| 39273415 | Renoprotective Effects of Daprodustat in Patients with Chronic Kidney Disease and Renal Anemia. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39273415 | PubMed |
| 39050745 | Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systematic review and network meta-analysis. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39050745 | PubMed |
| 38664033 | [Effect of salvia miltiorrhiza combined with roxadustat on wound healing of full-thickness skin defects in diabetic rats and its mechanism]. | Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi | 2024 | https://conductscience.org/library/papers/38664033 | PubMed |
| 38345037 | Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis. | Ren Fail | 2024 | https://conductscience.org/library/papers/38345037 | PubMed |
| 38280066 | Roxadustat and Oral Iron Absorption in Chinese Patients with Anemia of Chronic Kidney Disease: A Randomized, Open-Label, Phase 4 Study (ALTAI). | Adv Ther | 2024 | https://conductscience.org/library/papers/38280066 | PubMed |
| 38279224 | Tubular Endogenous Erythropoietin Protects Renal Function against Ischemic Reperfusion Injury. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38279224 | PubMed |
| 38098876 | Iron Supplements Concomitant within Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitors in the Treatment of Chronic Kidney Disease Anemia. | Kidney Dis (Basel) | 2023 | https://conductscience.org/library/papers/38098876 | PubMed |
| 37724564 | An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease. | Ren Fail | 2023 | https://conductscience.org/library/papers/37724564 | PubMed |
| 37654676 | FG-4592 relieves diabetic kidney disease severity by influencing metabolic profiles via gut microbiota reconstruction in both human and mouse models. | Front Physiol | 2023 | https://conductscience.org/library/papers/37654676 | PubMed |
| 37562670 | Myeloid Hif2α is not essential to maintain systemic iron homeostasis. | Exp Hematol | 2023 | https://conductscience.org/library/papers/37562670 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CP | 1356 | PubTator's text mining | https://conductscience.org/library/genes/1356 | NCBI Gene |
| EPO | 2056 | PubTator's text mining | https://conductscience.org/library/genes/2056 | NCBI Gene |
| HAMP | 57817 | PubTator's text mining | https://conductscience.org/library/genes/57817 | NCBI Gene |
| TF | 7018 | PubTator's text mining | https://conductscience.org/library/genes/7018 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| ROXADUSTAT | CHEMBL2338329 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2338329 |
Source ChEMBL
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| figshare | 10.6084/m9.figshare.7880417 |
Source figshare
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30953333
GET https://conductscience.org/api/papers/v1/30953333/references?page=2